Overview

Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma

Status:
Unknown status
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This phase II multi-institutional trial will explore the safety and efficacy of lenalidomide monotherapy given as maintenance therapy following salvage chemo-immunotherapy in patients with relapsed or refractory chemosensitive diffuse large B-cell lymphoma
Phase:
Phase 2
Details
Lead Sponsor:
IRCCS San Raffaele
Collaborator:
Celgene Corporation
Treatments:
Lenalidomide
Thalidomide